Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D000284:Administration, Oral; D001682:Biological Availability; D001853:Bone Marrow / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D001854:Bone Marrow Cells; D002250:Carbon Radioisotopes; D002986:Clinical Trials as Topic; D003857:Deoxyuridine / Q000037:antagonists & inhibitors / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage* / Q000032:analysis / Q000097:blood / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D014677:Pharmaceutical Vehicles; D013936:Thymidine / Q000037:antagonists & inhibitors / Q000378:metabolism; D013997:Time Factors
D002250:Carbon Radioisotopes; D014677:Pharmaceutical Vehicles; D005472:Fluorouracil; D013936:Thymidine; D003857:Deoxyuridine